Atsushi Imaizumi

This inventor holds 15 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Teijin Limited, Theravalues Corporation, Therabiopharma Inc.. Active years: 1985-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Atsushi Imaizumi. Retrieved from https://idiyas.com/inventor/atsushi-imaizumi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 2)

% Patents Active = 93.3

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 44(Granted Patents)

Location History:

Tokyo, JP (1989 - 2007)
Hino, JP (1985 - 2024)

Company Filing History:

Theravalues Corporation

National Hospital Organization

patents

6. 1 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

7. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1985-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12616665 - Neutrophil-to-lymphocyte ratio decreasing agent (2026-05-05),

2. 11986530 - Drug composition for parenteral administration (2024-05-21),

3. 11911348 - Therapeutic agent for cancer (2024-02-27),

4. 10849862 - Formulation of curcumin and anti-PD-1 antibody (2020-12-01),

5. 10245238 - Composition for oral intake (2019-04-02),

6. 7163933 - Treating agent for Paget's disease of bone (2007-01-16),

7. 6627732 - Glutathione derivatives and their dosage forms (2003-09-30),

8. 6346634 - Chemical compound containing a superoxide scavenger and an organic nitrate or nitrite moiety (2002-02-12),

9. 5851983 - Elastase inhibitory polypeptide and process for production thereof by (1998-12-22),

10. 5374713 - Peptide inhibitors of phospholipase A.sub.2 purified from inflammatory (1994-12-20),

11. 5344764 - Protein inhibitors of phospholipase A.sub.2 purified from inflammatory (1994-09-06),

12. 5223255 - Bordetella pertussis variants (1993-06-29),

13. 5116942 - Protein having an inflammatory phospholipase A.sub.2 inhibitory activity (1992-05-26),

14. 4810780 - Protein having phospholipase A2 inhibitory activity (1989-03-07),

15. 4500639 - Culturing Bordetella in media containing etherified cyclodextrin (1985-02-19),

Title: Atsushi Imaizumi: Innovator in Pharmaceutical Advancements

Introduction

Atsushi Imaizumi is a prominent inventor based in Hino, Japan, known for his significant contributions to the field of pharmaceuticals. With a total of 14 patents to his name, he has made remarkable strides in developing innovative drug compositions and therapeutic agents.

Latest Patents

Imaizumi's latest patents include a drug composition for parenteral administration, which features a highly water-soluble curcumin pharmaceutical preparation. This preparation is designed to maintain a sufficiently high concentration of free curcumin in the blood when administered parenterally, ensuring effective pharmacological action while maintaining high safety standards. Another notable patent is a therapeutic agent for cancer, which combines curcumin or its derivatives with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies to enhance therapeutic effects against cancer.

Career Highlights

Throughout his career, Atsushi Imaizumi has worked with notable companies such as Teijin Limited and Theravalues Corporation. His work in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Imaizumi has collaborated with esteemed colleagues, including Masahiro Okada and Yorimasa Suwa, to further enhance his research and development efforts in the pharmaceutical industry.

Conclusion

Atsushi Imaizumi's work exemplifies the spirit of innovation in the pharmaceutical field. His contributions through patents and collaborations continue to pave the way for advancements in drug therapies and cancer treatment.

Profile summary based on public USPTO records.